CL2023000553A1 - Uso de un anticuerpo anti-pd-1 y un fármaco antineoplásico citotóxico - Google Patents

Uso de un anticuerpo anti-pd-1 y un fármaco antineoplásico citotóxico

Info

Publication number
CL2023000553A1
CL2023000553A1 CL2023000553A CL2023000553A CL2023000553A1 CL 2023000553 A1 CL2023000553 A1 CL 2023000553A1 CL 2023000553 A CL2023000553 A CL 2023000553A CL 2023000553 A CL2023000553 A CL 2023000553A CL 2023000553 A1 CL2023000553 A1 CL 2023000553A1
Authority
CL
Chile
Prior art keywords
antibody
antineoplastic drug
combination
drug
cytotoxic antineoplastic
Prior art date
Application number
CL2023000553A
Other languages
English (en)
Inventor
Yao Sheng
Feng Hui
Original Assignee
Shanghai Junshi Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Junshi Biosciences Co Ltd filed Critical Shanghai Junshi Biosciences Co Ltd
Publication of CL2023000553A1 publication Critical patent/CL2023000553A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una combinación de un anticuerpo anti-PD-1 o un fragmento de unión a antígeno del anticuerpo anti-PD-1 y un fármaco antineoplásico citotóxico, y al uso de la combinación en la preparación de un medicamento para tratar el cáncer de pulmón no microcítico. Específicamente, la presente invención se refiere a una combinación de un anticuerpo anti-PD-1 o un fragmento de unión a antígeno del anticuerpo anti-PD-1, un fármaco antineoplásico antimetabolismo del folato y un fármaco antineoplásico de platino, y al uso de la combinación en la preparación de un medicamento para tratar el cáncer de pulmón no microcítico cuyo tratamiento con ITC del EGFR ha fracasado.
CL2023000553A 2020-08-28 2023-02-24 Uso de un anticuerpo anti-pd-1 y un fármaco antineoplásico citotóxico CL2023000553A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010883912 2020-08-28
CN202110925375 2021-08-12

Publications (1)

Publication Number Publication Date
CL2023000553A1 true CL2023000553A1 (es) 2023-08-25

Family

ID=80352732

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000553A CL2023000553A1 (es) 2020-08-28 2023-02-24 Uso de un anticuerpo anti-pd-1 y un fármaco antineoplásico citotóxico

Country Status (10)

Country Link
US (1) US20230322930A1 (es)
EP (1) EP4204009A1 (es)
JP (1) JP2023539506A (es)
CN (1) CN115518162A (es)
AU (1) AU2021330883A1 (es)
BR (1) BR112023003154A2 (es)
CA (1) CA3191131A1 (es)
CL (1) CL2023000553A1 (es)
MX (1) MX2023002278A (es)
WO (1) WO2022042681A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113893342B (zh) * 2021-10-11 2024-01-30 蒋涛 一种含有抗pd-1抗体的药物组合物在制备治疗晚期非小细胞肺癌药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104250302B (zh) * 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
CN109806393B (zh) * 2017-11-17 2022-07-26 江苏恒瑞医药股份有限公司 抗pd-1抗体、培美曲塞和铂类药物联合治疗非小细胞肺癌的用途
JP7477885B2 (ja) * 2018-06-22 2024-05-02 キュージーン インコーポレイテッド サイトカインをベースとした生理活性化薬剤およびその使用方法
CN110812485A (zh) * 2018-08-10 2020-02-21 江苏恒瑞医药股份有限公司 抗pd-1抗体联合化学疗法在制备治疗肿瘤的药物中的用途
CN110882385B (zh) * 2018-09-07 2021-07-09 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗肿瘤中的用途
WO2020092924A1 (en) * 2018-11-02 2020-05-07 Board Of Regents, The University Of Texas System Combination therapy for the treatment of egfr tyrosine kinase inhibitor resistant cancer

Also Published As

Publication number Publication date
WO2022042681A1 (en) 2022-03-03
CN115518162A (zh) 2022-12-27
EP4204009A1 (en) 2023-07-05
BR112023003154A2 (pt) 2023-04-04
AU2021330883A9 (en) 2023-07-13
JP2023539506A (ja) 2023-09-14
US20230322930A1 (en) 2023-10-12
AU2021330883A1 (en) 2023-05-11
MX2023002278A (es) 2023-03-10
CA3191131A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
NI201900112A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso.
CY1122366T1 (el) Θεραπεια της οξειας λεμφοβλαστικης λευχαιμιας
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
CY1122428T1 (el) Θεραπευτικη αγωγη της παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας με διειδικα αντισωματα εναντι cd3xcd19
ES2535404T3 (es) Uso de anticuerpo anti-VEGF en combinación con quimioterapia para tratar cáncer de mama
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
DOP2016000133A (es) Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este
BR112022003589A2 (pt) Conjugado de anticorpo-fármaco compreendendo anticorpo contra ror1 humano e uso para o mesmo
CL2019000485A1 (es) Uso de pridopidina para el tratamiento de la disminución funcional.
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
BR112016012506A2 (pt) Combinações farmacêuticas, seus usos, e uso de um portador de dados
AR108021A1 (es) Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
CL2023000553A1 (es) Uso de un anticuerpo anti-pd-1 y un fármaco antineoplásico citotóxico
CY1118499T1 (el) Χρηση ενος αναστολεα αρωματασης για την αντιμετωπιση υπογοναδισμου και σχετικων νοσων
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
CY1125014T1 (el) Υποκατεστημενα παραγωγα ξανθινης
BR112021014854A2 (pt) Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
MX2020010119A (es) Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo.
MX2023002805A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos.
BR112023000675A2 (pt) Terapia de combinação para tratamento de crescimento celular anormal
WO2018187698A3 (en) Combination therapies using caspase-1 dependent anticancer agents and pge2 antagonists
NO20044498L (no) Kombinasjonsterapi for behandling av cancer